Skip to main content
. 2015 Nov 19;15:163. doi: 10.1186/s12876-015-0390-3

Table 1.

Baseline demographic variables of the 99 patients with active Crohn’s disease who were assigned to intensive GMA or to weekly GMA in this study

Demography Intensive GMA Weekly GMA P value
(n = 54) (n = 45)
Male gender - n (%) 34 (63.0) 24 (53.3) 0.4133
Age, year 31.5 [24.8–40.5] 30.0 [23.5–43.0] 0.8965
Duration of disease, month 36.0 [5.5–138.0] 44.0 [11.5–93.0] 0.7081
Hospitalization - n (%) 27 (50.0) 22 (48.9) 1.0000
CDAI 260 [235–310] 259 [224–320] 0.9300
Disease location - n (%)
 Colon 23 (42.6) 17 (37.8) 0.6838
 Ileum and colon 31 (57.4) 28 (62.2) 0.6838
Surgical history – n (%) 13 (24.1) 15 (33.3) 0.3724
Previous biologics treatment - n (%) 10 (18.5) 10 (22.2) 0.8022
Concomitant medication - n (%)
 5-Aminosalicylates 46 (85.2) 37 (82.2) 0.7865
 Corticosteroids 8 (14.8) 8 (17.8) 0.7865
 Azathioprine 7 (13.0) 9 (20.0) 0.4157
 6-Mercaptopurine 3 (5.6) 2 (4.4) 1.0000
Nutrition therapy – n (%) 37 (68.5) 31 (68.9) 1.0000

Continuous variables are presented as the median [interquartile range] and were compared by the Wilcoxon-Mann–Whitney test. Categorical variables are presented as patient’s number (%) and were compared by the Fisher’s exact test. CDAI, Chrohn’s disease activity index; GMA, granulocyte and monocyte adsorptive apheresis